Kura Oncology (NASDAQ:KURA) Sets New 12-Month Low – Here’s What Happened

Kura Oncology, Inc. (NASDAQ:KURA)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $8.76 and last traded at $8.94, with a volume of 1384631 shares trading hands. The stock had previously closed at $9.01.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KURA. Jefferies Financial Group dropped their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. UBS Group initiated coverage on shares of Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.86.

Kura Oncology Stock Performance

The company has a 50-day simple moving average of $13.92 and a 200 day simple moving average of $17.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. nVerses Capital LLC purchased a new stake in shares of Kura Oncology during the 3rd quarter worth about $25,000. Point72 DIFC Ltd acquired a new position in Kura Oncology in the 3rd quarter worth about $146,000. Quarry LP purchased a new position in Kura Oncology during the second quarter worth approximately $196,000. Erste Asset Management GmbH acquired a new stake in Kura Oncology in the third quarter valued at approximately $215,000. Finally, Bellevue Group AG increased its position in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.